53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Description

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Conditions

Osteoarthritis (OA) of the Knee

Talk to us

Study Overview

On this page

Study Details

Study overview

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

A Randomized, Double-blind, Placebo-controlled, 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Severe Tibio- Femoral Osteoarthritis of the Knee

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Condition
Osteoarthritis (OA) of the Knee
Intervention / Treatment

-

Contacts and Locations

Mobile

AMR Mobile, Mobile, Alabama, United States, 36608

Scottsdale

Elite Clinical Network, Scottsdale, Arizona, United States, 85260

Tucson

Noble Clinical Research, Tucson, Arizona, United States, 85704

Carrolton

Legent Orthopedic Hospital, Carrolton, California, United States, 75006

Covina

Medvin Clinical Research, Covina, California, United States, 91722

Encinitas

CORE Orthopaedic Medical Center, Encinitas, California, United States, 92024

Huntington Beach

Marvel Clinical Research (Elite Clinical Network), Huntington Beach, California, United States, 92647

Riverside

Medvin Clinical Research Center, Riverside, California, United States, 92518

Tujunga

Medvin Clinical Research Center, Tujunga, California, United States, 91042

Whittier

Medvin Clinical Research Center, Whittier, California, United States, 90602

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    50 Years to 80 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    OrthoTrophix, Inc,

    Dawn McGuire - Chief Medical Officer, M.D. FAAN, STUDY_CHAIR, OrthoTrophix, Inc

    Study Record Dates

    2027-06-15